246 related articles for article (PubMed ID: 29520813)
1. A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
Wu Y; Yu H; Zheng SL; Na R; Mamawala M; Landis T; Wiley K; Petkewicz J; Shah S; Shi Z; Novakovic K; McGuire M; Brendler CB; Ding Q; Helfand BT; Carter HB; Cooney KA; Isaacs WB; Xu J
Prostate; 2018 Jun; 78(8):607-615. PubMed ID: 29520813
[TBL] [Abstract][Full Text] [Related]
2. Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
Wu Y; Yu H; Zheng SL; Feng B; Kapron AL; Na R; Boyle JL; Shah S; Shi Z; Ewing CM; Wiley KE; Luo J; Walsh PC; Carter HB; Helfand BT; Cooney KA; Xu J; Isaacs WB
Prostate; 2018 Dec; 78(16):1222-1228. PubMed ID: 30043417
[TBL] [Abstract][Full Text] [Related]
3. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
4. The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
Alorjani M; Aburub M; Al-Trad B; Hamad MA; AbuAlarja M; Bashir SA; Al-Batayneh K; Zoubi MA
Med Arch; 2023 Feb; 77(1):8-12. PubMed ID: 36919124
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
6. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
7. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
8. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
[TBL] [Abstract][Full Text] [Related]
9. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
[TBL] [Abstract][Full Text] [Related]
10. Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
Shi Z; Lu L; Resurreccion WK; Yang W; Wei J; Wang Q; Engelmann V; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2022 Jan; 82(1):107-119. PubMed ID: 34674288
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Clinical and Genetic Analysis of
Kirchner K; Gamulin M; Kulis T; Sievers B; Kastelan Z; Lessel D
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360192
[TBL] [Abstract][Full Text] [Related]
12. CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.
Apostolou P; Fostira F; Papamentzelopoulou M; Michelli M; Panopoulos C; Fountzilas G; Konstantopoulou I; Voutsinas GE; Yannoukakos D
Cancer Genet; 2015 Apr; 208(4):129-34. PubMed ID: 25835597
[TBL] [Abstract][Full Text] [Related]
13. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
Bell DW; Kim SH; Godwin AK; Schiripo TA; Harris PL; Haserlat SM; Wahrer DC; Haiman CA; Daly MB; Niendorf KB; Smith MR; Sgroi DC; Garber JE; Olopade OI; Le Marchand L; Henderson BE; Altshuler D; Haber DA; Freedman ML
Int J Cancer; 2007 Dec; 121(12):2661-7. PubMed ID: 17721994
[TBL] [Abstract][Full Text] [Related]
14. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
[TBL] [Abstract][Full Text] [Related]
15. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
[TBL] [Abstract][Full Text] [Related]
16. A novel founder CHEK2 mutation is associated with increased prostate cancer risk.
Cybulski C; Huzarski T; Górski B; Masojć B; Mierzejewski M; Debniak T; Gliniewicz B; Matyjasik J; Złowocka E; Kurzawski G; Sikorski A; Posmyk M; Szwiec M; Czajka R; Narod SA; Lubiński J
Cancer Res; 2004 Apr; 64(8):2677-9. PubMed ID: 15087378
[TBL] [Abstract][Full Text] [Related]
17. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
[TBL] [Abstract][Full Text] [Related]
18. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
19. Generation of two induced pluripotent stem cell lines from blood cells of a prostate cancer patient carrying germline mutation in CHEK2.
Liu R; Qian K; Xiao Y; Jiang W
Stem Cell Res; 2021 May; 53():102299. PubMed ID: 33780728
[TBL] [Abstract][Full Text] [Related]
20. Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.
Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
